Having co-founded BeiGene in 2010, John Oyler and Dr. Xiaodong Wang set out to build a unique company that was globally focused from its inception, to develop novel cancer therapies where there is global unmet need. BeiGene’s mission is to build a next generation biotechnology company, the first one that expands the highest quality therapies to billions more people.
Our corporate video provides insights into the history, development, current status and future of BeiGene.
More than 10 molecules have been advanced into the clinic since 2010.
BRUKINSKA® (zanubrutinib) is BeiGene’s first commercially approved treatment in the United States.
BeiGene is a well-developed and rapidly expanding global company with 80+ ongoing clinical trials in 35+ countries or regions.
Cancer has no borders. Neither do we.